ArticleACS omega2020
IC
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 37 citations in OpenAlex.
- Amphiphilic Semisynthetic Triterpenoids Impair Survival Pathways and Suppress Clonogenic Growth in Multidrug-Resistant High-Risk Neuroblastoma.International journal of molecular sciences · 2026Article
- Green Tea-Driven Green Synthesis of a Curcumin@Platinum Nanohybrid with Multifunctional Antioxidant, Burn-Healing Agent, and Selective Anticancer against PANC-1 Pancreatic Cancer Cells.Cell biochemistry and biophysics · 2026Article
- Single-cell in situ mapping of glioblastoma and astrocyte cell lines treated with a carbon dot-mediated riluzole nanotherapeutic agent: a live-cell µFTIR and soft X-ray tomography approach.Journal of nanobiotechnology · 2025Article
- Exploring the Potential of a New Nickel(II):Phenanthroline Complex with L-isoleucine as an Antitumor Agent: Design, Crystal Structure, Spectroscopic Characterization, and Theoretical Insights.Molecules (Basel, Switzerland) · 2025Article
- Dopamine stabilized in ultra-nanoreservoirs for controlled delivery in parkinson's disease.Nanomedicine (London, England) · 2025Article
- Assessment of Cell Viability in Drug Therapy: IC50 and Other New Time-Independent Indices for Evaluating Chemotherapy Efficacy.Pharmaceutics · 2025Article
- Solid CaCOCurrent cancer drug targets · 2025Article
- The RAL Small G Proteins Are Clinically Relevant Targets in Triple Negative Breast Cancer.Cancers · 2024Article
- Cytotoxic Cu(II) Complexes with a Novel Quinoline Derivative Ligand: Synthesis, Molecular Docking, and Biological Activity Analysis.ACS omega · 2024Article
- Nanocarrier-mediated cancer therapy with cisplatin:Heliyon · 2024Article
- Comparative efficacy ofPeerJ · 2024Article
- The Cytotoxicity ofCurrent issues in molecular biology · 2023Article
- Catalytic Nanomedicine as a Therapeutic Approach to Brain Tumors: Main Hypotheses for Mechanisms of Action.Nanomaterials (Basel, Switzerland) · 2023Article
- Phototoxic Potential of Different DNA Intercalators for Skin Cancer Therapy: In Vitro Screening.International journal of molecular sciences · 2023Article
- Exploration of a predictive model based on genes associated with fatty acid metabolism and clinical treatment for head and neck squamous cell carcinoma.Journal of clinical laboratory analysis · 2022Article
- Network pharmacology-based analysis for unraveling potential cancer-related molecular targets of Egyptian propolis phytoconstituents accompanied with molecular docking andRSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a major public health problem being one of the main causes of morbidity and mortality today. Recent advances in catalytic nanomedicine have offered new cancer therapies based on the administration of nanoparticles (NPs) of platinum (Pt) dispersed in catalytic mesoporous nanomaterials (titania, TiO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.